Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2018, it provided inpatient services through a network of 425 skilled nursing and assisted/senior living facilities, including 399 skilled nursing facilities and 26 stand-alone assisted/senior living facilities across 29 states. Genesis HealthCare, Inc. also supplies rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 46 states and the District of Columbia. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.
Industry, Sector and Symbol
Industry Skilled nursing care facilities
Sub-IndustryN/A
SectorMedical
Phone610-444-6350
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.98 billion
Profitability
Miscellaneous
Employees61,300
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Genesis Healthcare (NYSE:GEN) Frequently Asked Questions
What is Genesis Healthcare's stock symbol?
Genesis Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "GEN."
How were Genesis Healthcare's earnings last quarter?
Genesis Healthcare Inc (NYSE:GEN) issued its earnings results on Monday, March, 18th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.43. The firm earned $1.19 billion during the quarter, compared to analysts' expectations of $1.21 billion. During the same quarter last year, the business earned ($0.92) earnings per share. View Genesis Healthcare's Earnings History.
When is Genesis Healthcare's next earnings date?
What price target have analysts set for GEN?
3 analysts have issued 1 year price targets for Genesis Healthcare's shares. Their predictions range from $1.75 to $7.00. On average, they anticipate Genesis Healthcare's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 184.1% from the stock's current price. View Analyst Price Targets for Genesis Healthcare.
What is the consensus analysts' recommendation for Genesis Healthcare?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genesis Healthcare in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genesis Healthcare.
Has Genesis Healthcare been receiving favorable news coverage?
News articles about GEN stock have trended positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genesis Healthcare earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the next several days.
Who are some of Genesis Healthcare's key competitors?
Some companies that are related to Genesis Healthcare include Global Cord Blood (CO), Advanz Pharma (CXRXF), Cellectis (CLLS), Addus Homecare (ADUS), Homology Medicines (FIXX), Retrophin (RTRX), Natus Medical (BABY), ANI Pharmaceuticals (ANIP), Draegerwerk AG & Co KGaA (DRW3), AxoGen (AXGN), Shockwave Medical (SWAV), Twist Bioscience (TWST), MacroGenics (MGNX), Cerus (CERS) and Akebia Therapeutics (AKBA).
What other stocks do shareholders of Genesis Healthcare own?
Who are Genesis Healthcare's key executives?
Genesis Healthcare's management team includes the folowing people:
- Mr. George V. Hager Jr., CEO & Director (Age 63)
- Mr. Thomas DiVittorio, CFO, Sr. VP, Treasurer & Assistant Sec. (Age 51)
- Mr. Paul David Bach, COO & Exec. VP (Age 60)
- Dr. JoAnne Susan Reifsnyder Ph.D., MSN, MBA, FAAN, Exec. VP of Clinical Operations & Chief Nursing Officer (Age 60)
- Mr. Richard L. Castor, Chief Information Officer & Sr. VP (Age 64)
How do I buy shares of Genesis Healthcare?
Shares of GEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genesis Healthcare's stock price today?
One share of GEN stock can currently be purchased for approximately $1.32.
How big of a company is Genesis Healthcare?
Genesis Healthcare has a market capitalization of $213.55 million and generates $4.98 billion in revenue each year. The company earns $-235,230,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Genesis Healthcare employs 61,300 workers across the globe.
What is Genesis Healthcare's official website?
How can I contact Genesis Healthcare?
Genesis Healthcare's mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company can be reached via phone at 610-444-6350 or via email at [email protected]
MarketBeat Community Rating for Genesis Healthcare (NYSE GEN)
MarketBeat's community ratings are surveys of what our community members think about Genesis Healthcare and other stocks. Vote "Outperform" if you believe GEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
